Table 1.

Baseline characteristics of patients undergoing real-time rescue use of plerixafor

	G-CSF Alone (n=13)	Chemo + G-CSF (n=26)	Total (n=39)
Median age (range)	64y (55–73y)	57y (42–68y)	62y (26–73y)
Diagnosis
Non-Hodgkin lymphoma	7	16	23
Hodgkin lymphoma	0	1	1
Multiple Myeloma	5	9	14
Amyloidosis	1	0	1
Median # of prior regimens (range)	2 (1–4)	2 (1–8)	2 (1–8)
Prior lenalidomide (%)	5	9	14 (36%)
Prior fludarabine (%)	0	2	2 (5%)
Prior pelvic or spinal radiation	Spinal 2 Pelvic 1	Spinal 1 Pelvic 2	6 (15%)
Prior failed mobilization (%)	3	5	8 (21%)
Prior ASCT (%)	1	0	1 (3%)
Reason for rescue use of plerixafor (%)
Low blood CD34+ cell concentration	8	22	30 (77%)
Low initial apheresis CD34+ cell yield	4	3	7 (18%)
Waning apheresis CD34+ cell yield	0	1	1 (3%)
Clinical delay in apheresis	1	0	1 (3%)

Note: To provide complete data for each rescue use of plerixafor the one patient receiving 2 rescue attempts is listed twice.